Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir triple therapy in insulin-resistant HCV genotype 1 patients who previously failed peginterferon plus ribavirin
2012-002771-33Phase 4Terminated
- Sponsor
- MSD
- Start
- Dec 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of boceprevir in hepatitis C virus infection, sponsored by MSD. Primary endpoint: Sustained virological response at 24 weeks. Started Dec 2012; status: terminated.
02
Drugs
boceprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-002771-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002771-33.